Clinical trials
CAROLINA
III phase

PRECISION
III phase
A Randomized, Double Blind, Parallel-Group Study Of Cardiovascular Safety In Osteoarthritis or Rheumatoid Arthritis
Patients With or at High Risk for Cardiovascular disease Comparing Celecoxib With Naproxen and Ibuprofen.

GS-US-259-0110
III phase
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Glucose Lowering
Effects and Safety of a Novel Study Drug When Added to Glimepiride in Subjects with Type 2 Diabetes Mellitus
GS-US-259-0131
III phase
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of a Novel
Study Drug as Monotherapy for Type 2 Diabetes Mellitus
MKC-TI-030
III phase
Pulmonary Outcomes within a 2-Year Period in Subjects with Diabetes Mellitus Treated with Technosphere®/Insulin
or Usual Antidiabetic Treatment and in Subjects without Abnormalities in Glucose Control.

MKC-TI-103
III phase
Zolip
(C LF0242780-01 05 01) III phase
A multicenter, double-blind, randomized, active comparator, forced-titration study to compare the efficacy and
safety of the combination of 145 mg fenofibrate and 20 or 40 mg simvastatin with 40 mg simvastatin monotherapy
in patient with mixed dyslipidemia at risk of
cardiovascular disease not adequately controlled by 20 mg simvastatin alone.
Shift (CL3-16257-063)
III phase
CONDOR (A3191084)
IV phase
Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study to Compare Celecoxib (200 mg BID) with
Diclofenac SR (75 mg BID) plus Omeprazole (20 mg QD) for Gastrointestinal Events in Subjects with Osteoarthritis
and Reumatoid Arthritis at High-Risk of Gastrointestinal Adverse Events.

FAIR-HF
III phase

ARISTOTLE (CV185030)
III phase
A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and  
Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects with Nonvalvular Atrial Fibrillation.

СV 185-036
III phase

CCD-0605-PR-0021
III phase
A 24-week, multicenter, multinational, randomized, double-blind, triple-dummy, 3-arm parallel group study  
comparing the efficacy and safety of CHF 1535 200/6 (beclomethasone dipropionate 200 ug plus formoterol 6  
ug/actuation), 2 puffs b.i.d., versus beclomethasone diproprionate HFA (250 ug/actuation), 4 puffs b.i.d., versus  
Seretide® 500/50 (fluticasone 500 ug plus salmeterol 50 ug/actuation), 1 inhalation b.i.d., in patients with severe  
asthma.
“A phase 3, 24-Week, Multi-Center, Open-Label, Randomized, Controlled Trial Comparing the Efficacy and Safety of
Prandial Inhalation of Technosphere®/Insulin in Combination with Metformin or Technosphere®/Insulin Alone
Versus 2 Oral Antidiabetic Agents (Metformin and a Secretagougue) in Subjects With Type 2 Diabetes Mellitus Sub-
Optimally Controlled on Combination Metformin and a Secretagogue”.
Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left
ventricular systolic dysfunction
A three-year randomised double-blind placebo-controlled international multicentre study.
Randomized, Double-Blind, Controlled Trial III phase, assessment the efficacy and safety of the Ferinject® with
comparison to the placebo in patients with Iron deficiency and chronic Heart Failure.
A phase III randomized, double-blind, parallel-group, multi-center study of the safety and efficacy of Apixaban for  
prophylaxis of venous thromboembolism in acutely ill medical subjects during and following hospitalization.

MDX1100-04
II phase

ТАК-783
II phase
A Randomized, Double-blind, Placebo-Controlled Proof of Concept Study to Evaluate the Safety and Efficacy of Oral  
TAK-783 in the Treatment of the Signs and Symptoms in Subjects with Rheumatoid Arthritis.
A Phase 2 Multi-dose, Double-blind, Placebo-controlled, Randomized, Multicenter study of MDX-1100 (anti-CXCL10
Human Monoclonal Antibody) in Patients with Active Rheumatoid Arthritis (RA).
POET (205.389)
IV phase


MB 102-021
III phase
A Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3 Trial Evaluate the Safety and
Efficacy of Dapagliflozin in Combination with Metformin as Initial Therapy as Compared with Dapagliflozin
Monotherapy and Metformin Monotherapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control.
BC21625
DM III phase

CS8635-A-E30X
III phase
A randomized, double-blind, parallel-group add-on study of hydrochlorothiazide in subjects with moderate to severe
hypertension not achieving target blood pressure on olmesartan medoxomil/amlodipine fixed dose combination
40/10 mg alone.
A multicenter, randomized, open label, active-comparator controlled study to assess the efficacy, safety and
tolerability of taspoglutide compared to
exenatide in patients with type 2 diabetes mellitus inadequately controlled with
metformin, thiazolidinedione or a combination of both.

CARAT 2
II phase

FELT, (REC 15/2375-IT-CL 0336)
III phase
An international multicentre, randomized, parallel group, double-blind trial to evaluate different dose combinations
of
Lercanidipine and enalapril in comparison with each component administered alone and with placebo in patients
with essential hypertension
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX354-C in
Subjects with Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy.

MI-CP219 II phase

MKI113006
II phase
Study Administration Information for A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter,
Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod (GW856553) Tablets Administered Twice
Daily compared with Placebo for 24 Weeks in Adult Subjects with Chronic Obstructive Pulmonary Disease (COPD).
A Phase 2 Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Efficacy
and Safety of CAM-3001 in Subjects with Rheumatoid Arthritis.




A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of
linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high cardiovascular risk.
Effect of inhalation of tiotropium once daily 18 mcg versus salmeterol twice daily 50 mcg on time to first  
exacerbation in COPD patients (a  andomized, double-blind, double-dummy, parallel group, one-year study).

Ispra (А6141079)
III phase
The Effect of Eplerenone versus Placebo on Cardiovascular Mortality and Heart Failure Hospitalization in Patients
with NYHA Class II Chronic Systolic Heart Failure.
28431754 DIA3008
III phase
28431754 DIA3006
III phase
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel-Group, Multicenter Study to Evaluate
the Efficacy, Safety, and Tolerability of JNJ-28431754 (Canagliflozin) Compared with Sitagliptin and Placebo in the
Treatment of Subject with Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformine Monotherapy
A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431574 on
Cardiovascular out comes in Adult Subjects With Type2 Diabetes Mellitus, The CANVAS Trial (CANagliflozin cardio
Vascular Assessmen Study).
DB2114418
III phase
An exercise endurance study to evaluate the effects of treatment of COPD patients with a dual bronchodilator:
GSK573719/GW642444.
OSCIRIA 4
III phase
A Phase IIB, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and
Safety of Fostamatinib Disodium Monotherapy Compared with Adalimumab Monotherapy in Patients with Active
Rheumatoid Arthritis.
OSCIRIA 5
III phase
A Long-term Extension Study to Assess the Safety and Efficacy of Fostamatinib Disodium (FosD) in the Treatment of
Rheumatoid Arthritis
OSCIRIA 33
III phase
A Multi-Centre, Randomised, Double'Blind,Placebo- Controlled,ParalleFGroup Study of the Effect of
Fostamatinib100mg Twice Dailyon 24-hour Ambulatory Blood Pressurein Patients with RheumatoidArthritis

GS-US-259-0147
III phase
A Phase 3, Randomized, Double-blind, Placebo-controlled,Parallel group Study to Evaluate the Efficacy and Safety of
Ranolazine When Added to Metformin in Subjects with Type 2 Diabetes Mellitus







Copyright © 2014 - Zmeev S., Juravlev N., Tabachnikov V.
РусУкрEng
University site